Eli Lilly's once-weekly KwikPen format for Mounjaro has been approved in India, offering an easier delivery system for type 2 ...

Chinese researchers have discovered that the spleen could be instrumental in treating diabetes, following successful cell transplant experiments.

Eli Lilly's Mounjaro has seen a positive reception in India, capturing significant sales and market interest since its launch ...

India's obesity drug market is set for intense competition with Novo Nordisk launching Wegovy to challenge Eli Lilly's ...

China has an estimated 233 million diabetic patients by the year 2023, up 163 percent over 2005, latest study by Chinese ...

Researchers say nanoparticles could help engineer the spleen – a more promising long-term survival site than the liver – into ...

Mounjaro has sold more than 81,570 units in India, totalling about ₹23.94 crore ($2.76 million) as of May, with the drug ...

Innovent Biologics presents results from DREAMS-1 phase 3 study of mazdutide in Chinese adults with T2D at ADA Scientific Sessions: San Francisco Thursday, June 26, 2025, 14:00 Hr ...

Eli Lilly and Novo Nordisk intensify their weight-loss drug rivalry in India as rising demand and looming generics reshape a fast-growing market.

With obesity and Type 2 diabetes on the rise, India is emerging as a key battleground for global drugmakers developing next-generation therapies targeting metabolic disorders.